No. Our product provider (Platinum) does not use embryonic tissue. These products come from ethically sourced, donated perinatal tissue, including umbilical cord tissue, collected after full-term healthy births with donor consent.

Safety is a top priority. Platinum follows FDA regulations for tissue processing to support consistent quality and safety standards. The process starts with a thorough screening of the donor parents, along with an in-depth generational family health review, to confirm eligibility.

A documented chain of custody is maintained throughout the process. A recovery specialist collects the postnatal donation at the hospital and transports it directly to the laboratory. Once processed, all materials undergo a 14-day quarantine and are extensively tested for bacterial and disease contamination by a CLIA-certified lab to support a clean, high-quality final product.

Yes. Products provided by Platinum are designed to comply with U.S. FDA regulations governing human cells, tissues, and cellular and tissue-based products as defined under 21 CFR Part 1271.

No, blood type matching is not required. The materials utilized are derived from perinatal tissue, which has low immunogenicity characteristics in biological research. They are also processed within strictly sterile environments to reduce the risk of contamination. Because of these characteristics, perinatal tissue products are generally considered broadly compatible.

In many cases, labs outside the United States rely on expanded cells. As cells are expanded across generations, they can lose regenerative capacity over time.

In contrast, Keystone Biologics' products feature "master cells" — non-expanded, primary-passage cells derived directly from the original perinatal source material. Peer-reviewed research in cell biology has documented that extended ex vivo expansion can alter the biological characteristics of mesenchymal stromal cells, including changes to secretory profile and functional markers. By utilizing these cells at their earliest passage, this approach is designed to preserve the biological profile present in the source tissue at the time of donation.

HCT/P-based products are designed with biological properties intended to support the body's natural repair environment. In biological research, the growth factors, cytokines, and extracellular matrix proteins found in perinatal tissue have been studied for their ability to interact with and influence the local cellular environment in which they are introduced — characteristics associated in the literature with cellular signaling and tissue microenvironment dynamics.

At a cellular level, these products contain components that are associated in research literature with processes of cellular signaling and the natural dynamics of tissue environments.

No. HCT/P-based products are not categorized as performance-enhancing drugs.

Every patient's experience is unique. Response timelines vary based on the individual, the nature of their tissue concern, and other factors determined by their provider. Patients should discuss realistic expectations directly with their healthcare provider during consultation.

Platelet-Rich Plasma (PRP) uses components from your own blood. HCT/P-based products are derived from perinatal tissue, which may offer a different profile of growth factors and cytokines.

PRP is often delivered as a series of sessions, while an HCT/P-based option may be used as a single-application approach depending on the individual plan.